Both BRAF and MEK inhibitors mediate various cancer-cell-dependent immunostimulatory effects, including upregulation of tumor associated antigens and improved antigen presentation [[50], [51], [52], [53], [54]], induction of immunogenic cell death [55], secretion of TH1 cytokines such as CXCL9 and CXCL10 [53] and downregulation of immunosuppressive factors, including IL8, VEGFA, and the MDSC chemoattractant SPP1 [54,56,57]. The gene discussed is MAP2K7; the disease is neoplasm.